Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Axonis Therapeutics logo — Axonis Therapeutics is advancing breakthrough discoveries to...

Axonis Therapeutics

Axonis Therapeutics is advancing breakthrough discoveries to develop first-in-class therapies for neurological disorders

Founded 2019 United States Boston, United States 22 employees Series A Biotechnology, Life Sciences

General Information

Company Name Axonis Therapeutics
Founded Year 2019
Location United States Boston, United States
Employees 22
Industries Biotechnology, Life Sciences
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Axonis Therapeutics. To contact Axonis Therapeutics, visit axonis.us.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Axonis Therapeutics compare?

A PDF of Axonis Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Axonis Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Axonis Therapeutics

Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class medicines targeting KCC2, the critical mediator of inhibitory neurotransmission within the brain, by translating breakthrough discoveries spun out from Boston Children’s Hospital, Harvard and Laval University. The company has built a proprietary KCC2 discovery engine, based on several years of world-leading know-how, to become the leaders in this potentially blockbuster drug space. Axonis’ lead development candidate, AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for inhibitory neurotransmission, for the treatment of epilepsy and pain. Axonis recently closed a $115 Million Series A financing co-led by Cormorant Asset Management and venBio Partners with significant investments from Sofinnova Investments, MRL Ventures Fund (Merck & Co., Rahway, NJ), Perceptive Advisors, Solasta Ventures and Lumira Ventures. Axonis is grateful for grant awards received from NIH, DoD, Wings for Life, MLSC, Praxis SCI, CURE Epilepsy, ISSNL and SynGAP Foundation. The company is headquartered in Boston, MA. For more information, visit www.axonis.us.

Business keywords: Neuro-focused biotechnology, Drug Discovery, Neuroregeneration, Neuromodulation, Neuroprotection, Neurological Disorders, KCC2 Targeting, CNS Therapies, Epilepsy Treatment, Pain Management, Neuroscience Innovation, Oral Small Molecule Development, Neurological Research, Series A Financing, Biotech Investment

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Series A Undisclosed -
30 Oct 2024
Grant Undisclosed -
05 Apr 2023
Grant Undisclosed -
24 Sep 2022
Grant Undisclosed -
01 Mar 2022
Seed Undisclosed -
14 Jul 2021
Grant Undisclosed -
20 May 2021
Grant Undisclosed -
30 Sep 2020
Seed Undisclosed -
28 May 2020
Grant Undisclosed -
14 Jan 2020
Non Equity Assistance Undisclosed -
24 Oct 2019

Axonis Therapeutics Alternatives & Competitors

View All Alternatives
Axonis Therapeutics vs
Rapport Therapeutics
Rapport Therapeutics United States

Precision medicines to match the complexity of the human brain.

IPO
102 employees
Biotechnology, Health Care
Axonis Therapeutics vs
Proniras Corporation
Proniras Corporation United States

Clinical-stage biotechnology developing therapeutics for the treatment of substance use & specialty...

Series B
4 employees
Biotechnology, Health Care
Axonis Therapeutics vs
Allyx Therapeutics
Allyx Therapeutics United States

Protecting Synapses and Reversing Neurodegeneration

Venture round
5 employees
Biotechnology, Health Care
View all alternatives

FAQ About Axonis Therapeutics

Axonis Therapeutics is advancing breakthrough discoveries to develop first-in-class therapies for neurological disorders
Axonis Therapeutics was founded in 2019.
Axonis Therapeutics is headquartered in Boston, United States.
Axonis Therapeutics operates in Biotechnology and Life Sciences. Its work centres on Neuro-focused biotechnology, Drug Discovery, Neuroregeneration and Neuromodulation.
Axonis Therapeutics has approximately 22 employees.
Axonis Therapeutics has completed 10 funding rounds. The latest funding stage is Series A.
Top alternatives and competitors to Axonis Therapeutics include Rapport Therapeutics, Proniras Corporation, Allyx Therapeutics, Mission Therapeutics, VRise Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Axonis Therapeutics and Rapport Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Axonis Therapeutics, https://bouncewatch.com/company/axonis-therapeutics, updated 8 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes